These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32358917)

  • 1. Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial.
    Meessen JMTA; Cardinale D; Ciceri F; Sandri MT; Civelli M; Bottazzi B; Cucchi G; Menatti E; Mangiavacchi M; Condorelli G; Barbieri E; Gori S; Colombo A; Curigliano G; Salvatici M; Pastori P; Ghisoni F; Bianchi A; Falci C; Cortesi P; Farolfi A; Monopoli A; Milandri C; Bregni M; Malossi A; Nassiacos D; Verusio C; Staszewsky L; Leone R; Novelli D; Balconi G; Nicolis EB; Franzosi MG; Masson S; Garlanda C; Mantovani A; Cipolla CM; Latini R;
    ESC Heart Fail; 2020 Aug; 7(4):1452-1466. PubMed ID: 32358917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial.
    Cardinale D; Ciceri F; Latini R; Franzosi MG; Sandri MT; Civelli M; Cucchi G; Menatti E; Mangiavacchi M; Cavina R; Barbieri E; Gori S; Colombo A; Curigliano G; Salvatici M; Rizzo A; Ghisoni F; Bianchi A; Falci C; Aquilina M; Rocca A; Monopoli A; Milandri C; Rossetti G; Bregni M; Sicuro M; Malossi A; Nassiacos D; Verusio C; Giordano M; Staszewsky L; Barlera S; Nicolis EB; Magnoli M; Masson S; Cipolla CM;
    Eur J Cancer; 2018 May; 94():126-137. PubMed ID: 29567630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Detection and Prediction of Anthracycline-Induced Cardiotoxicity　- A Prospective Cohort Study.
    Inoue K; Machino-Ohtsuka T; Nakazawa Y; Iida N; Sasamura R; Bando H; Chiba S; Tasaka N; Ishizu T; Murakoshi N; Xu D; Sekine I; Tajiri K
    Circ J; 2024 Apr; 88(5):751-759. PubMed ID: 38462534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
    Mavinkurve-Groothuis AM; Marcus KA; Pourier M; Loonen J; Feuth T; Hoogerbrugge PM; de Korte CL; Kapusta L
    Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):562-9. PubMed ID: 23109647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
    Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
    Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
    Gulati G; Heck SL; Røsjø H; Ree AH; Hoffmann P; Hagve TA; Norseth J; Gravdehaug B; Steine K; Geisler J; Omland T
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29118031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?
    Malik A; Jeyaraj PA; Calton R; Uppal B; Negi P; Shankar A; Patil J; Mahajan MK
    Asian Pac J Cancer Prev; 2016; 17(4):2301-5. PubMed ID: 27221934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
    Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
    JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis.
    Michel L; Mincu RI; Mrotzek SM; Korste S; Neudorf U; Rassaf T; Totzeck M
    ESC Heart Fail; 2020 Apr; 7(2):423-433. PubMed ID: 32069386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy.
    Tzolos E; Adamson PD; Hall PS; Macpherson IR; Oikonomidou O; MacLean M; Lewis SC; McVicars H; Newby DE; Mills NL; Lang NN; Henriksen PA
    Clin Oncol (R Coll Radiol); 2020 May; 32(5):292-297. PubMed ID: 31813662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study.
    Mathew P; Suarez W; Kip K; Bayar E; Jasty R; Matloub Y; Raisch D
    Cancer Invest; 2001; 19(4):352-9. PubMed ID: 11405175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic value of global longitudinal strain combined with cardiac biomarkers on early detection of anthracycline-related cardiac dysfunction.
    Allam H; Kamal M; Bendary M; Osama A; El Eleimy HA; Bendary A
    J Echocardiogr; 2023 Dec; 21(4):165-172. PubMed ID: 37453981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
    Dodos F; Halbsguth T; Erdmann E; Hoppe UC
    Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Cardiac Biomarkers Assessment in Combination with Myocardial 2D Strain Echocardiography for Early Detection of Anthracycline-Related Cardiac Toxicity.
    Mahjoob MP; Sheikholeslami SA; Dadras M; Mansouri H; Haghi M; Naderian M; Sadeghi L; Tabary M; Khaheshi I
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(1):74-83. PubMed ID: 31513000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac Troponin I Predicts Elevated B-type Natriuretic Peptide in Patients Treated with Anthracycline-Containing Chemotherapy.
    Oikawa M; Yoshihisa A; Yokokawa T; Misaka T; Yaegashi D; Miyata M; Nakazato K; Ishida T; Takeishi Y
    Oncology; 2020; 98(9):653-660. PubMed ID: 32454480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.
    Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Cohen V; Gosavi S; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
    Am J Cardiol; 2011 May; 107(9):1375-80. PubMed ID: 21371685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines.
    Menna P; Salvatorelli E; Armento G; Annibali O; Greco C; Marchesi F; Calabrese V; Reggiardo G; Minotti G
    J Pharmacol Exp Ther; 2018 Dec; 367(3):518-527. PubMed ID: 30275150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left Ventricular Systolic Dysfunction Predicted By Early Troponin I Release After Anthracycline Based Chemotherapy In Breast Cancer Patients.
    Shafi A; Siddiqui N; Imtiaz S; Din Sajid MU
    J Ayub Med Coll Abbottabad; 2017; 29(2):266-269. PubMed ID: 28718245
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.